Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

12.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Prodrugs01:30

Prodrugs

4.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.5K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BioMedGraphica: an all-in-one platform for joint textual biomedical prior knowledge and numeric graph generation.

Bioinformatics (Oxford, England)·2026
Same author

Interpreting Omics Data Analysis with Large Language Models for Disease Target and Drug Discovery.

bioRxiv : the preprint server for biology·2026
Same author

SnakeAltPromoter Facilitates Differential Alternative Promoter Analysis.

Computational and structural biotechnology journal·2026
Same author

OmniCellTOSG: The First Cell Text-Omic Signaling Graphs Dataset for Graph Language Foundation Modeling.

Research square·2026
Same author

Multi-modal pediatric critical care datamart for extracorporeal support prediction and decision support.

JAMIA open·2026
Same author

Correction: Eliminating the AI digital divide by building local capacity.

PLOS digital health·2025

Related Experiment Video

Updated: Mar 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System.

Kelly Regan1, Soheil Moosavinasab2, Philip Payne3

  • 1Department of Biomedical Informatics, The Ohio State University; Kelly.Regan@osumc.edu.

Journal of Visualized Experiments : Jove
|January 7, 2017
PubMed
Summary

This study introduces "RE:fine Drugs," a novel computational tool for drug repurposing. It integrates genetic and clinical data to identify potential new uses for existing medications, aiming for faster and cheaper drug discovery.

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.8K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.8K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Area of Science:

  • Pharmacology
  • Genomics
  • Computational Biology

Background:

  • Drug repurposing offers a cost-effective alternative to de novo drug development.
  • High costs and lengthy approval times hinder traditional drug discovery pipelines.

Purpose of the Study:

  • To develop a computational method for identifying drug repurposing candidates.
  • To create an accessible tool for exploring drug-gene-disease relationships.

Main Methods:

  • Integration of genetic (GWAS) and clinical phenotype (PheWAS) data with drug information.
  • Development of a novel transitive Drug-Gene-Disease triad approach.
  • Creation of the interactive web-based dashboard "RE:fine Drugs".

Main Results:

  • "RE:fine Drugs" enables automated searches for drug repurposing candidates.
  • The tool prioritizes candidates based on literature support, GWAS/PheWAS associations, and molecular targets.
  • A case study demonstrates the system's functionalities and advanced search options.

Conclusions:

  • "RE:fine Drugs" provides a user-friendly platform for efficient drug repurposing candidate identification.
  • The integrated data approach facilitates safer, cheaper, and faster drug discovery.
  • This tool supports researchers in exploring novel therapeutic applications for existing drugs.